Original Article
Title:Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis
Short title: Tissue effect of mepolizumab in chronic rhinosinusitis
Sophie Walter, BMed MD BSc(Med)Hons1; Jacqueline Ho, MD1, 2; Raquel Alvarado, PhD1; Greg Smith, PhD3, David R. Croucher, PhD2, 5; Sharron Liang, MD6; Simone L. Van Es, MD3, 4; Peter Earls, MD1, 6; Janet Rimmer, MD MBBS1, 7, 8; Raewyn Campbell, MD1, 9, 10; Larry Kalish, MBBS MS MMed (Clin Epi)1, 11, 12; Raymond Sacks, MBBCh1, 10-12; Richard J. Harvey, MD PhD1, 10
  1. Rhinology and Skull Base Research Group, St Vincent’s Centre for Applied Medical Research, University of New South Wales, Sydney, Australia
  2. St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia
  3. School of Medical Sciences, University of New South Wales, Sydney, Australia
  4. New South Wales Health Education and Training Institute, Sydney, Australia
  5. Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
  6. Department of Anatomical Pathology, St Vincent’s Hospital, Sydney, Australia
  7. Woolcock Institute, University of Sydney, Sydney, Australia
  8. Faculty of Medicine, Notre Dame University, Sydney, Australia
  9. Department of Otolaryngology Head and Neck Surgery, Royal Prince Alfred Hospital, Sydney, Australia
  10. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
  11. Department of Otolaryngology, Head and Neck Surgery, Concord General Hospital, University of Sydney, Sydney, Australia
  12. Faculty of Medicine, University of Sydney, Sydney, Australia
Corresponding author: Sophie Walter; address: 67 Burton Street, Darlinghurst, New South Wales, 2010, Australia; Tel: +614 9360 4811; Fax: +614 9360 9919; Email: sophie.walter20@gmail.com